RGS9

Reference

1. ^ ^{а б} „Entrez Gene: RGS9 regulator of G-protein signalling 9”. 
2. ^ Martemyanov KA, Krispel CM, Lishko PV, Burns ME, Arshavsky VY (2008). „Functional comparison of RGS9 splice isoforms in a living cell”. Proceedings of the National Academy of Sciences of the United States of America. 105 (52): 20988—93. PMC 2634932 . PMID 19098104. doi:10.1073/pnas.0808941106. 
3. ^ Garzón J, Rodríguez-Díaz M, López-Fando A, Sánchez-Blázquez P (2001). „RGS9 proteins facilitate acute tolerance to mi-opioid effects”. The European Journal of Neuroscience. 13 (4): 801—11. PMID 11207815. doi:10.1046/j.0953-816x.2000.01444.x. 
4. ^ Zachariou V, Georgescu D, Sanchez N, Rahman Z, DiLeone R, Berton O, Neve RL, Sim-Selley LJ, Selley DE, Gold SJ, Nestler EJ (2003). „Essential role for RGS9 in opiate action”. Proceedings of the National Academy of Sciences of the United States of America. 100 (23): 13656—61. PMC 263869 . PMID 14595021. doi:10.1073/pnas.2232594100. 
5. ^ Sánchez-Blázquez P, Rodríguez-Muñoz M, Montero C, Garzón J (2005). „RGS-Rz and RGS9-2 proteins control mu-opioid receptor desensitisation in CNS: the role of activated Galphaz subunits”. Neuropharmacology. 48 (1): 134—50. PMID 15617734. doi:10.1016/j.neuropharm.2004.08.016. 
6. ^ Garzón J, Rodríguez-Muñoz M, López-Fando A, Sánchez-Blázquez P (2005). „Activation of mu-opioid receptors transfers control of Galpha subunits to the regulator of G-protein signaling RGS9-2: role in receptor desensitization”. The Journal of Biological Chemistry. 280 (10): 8951—60. PMID 15632124. doi:10.1074/jbc.M407005200. 
7. ^ Psifogeorgou K, Papakosta P, Russo SJ, Neve RL, Kardassis D, Gold SJ, Zachariou V (2007). „RGS9-2 is a negative modulator of mu-opioid receptor function”. Journal of Neurochemistry. 103 (2): 617—25. PMID 17725581. doi:10.1111/j.1471-4159.2007.04812.x. 
8. ^ Hooks SB, Martemyanov K, Zachariou V (2008). „A role of RGS proteins in drug addiction”. Biochemical Pharmacology. 75 (1): 76—84. PMID 17880927. doi:10.1016/j.bcp.2007.07.045. 
9. ^ Traynor JR, Terzi D, Caldarone BJ, Zachariou V (2009). „RGS9-2: probing an intracellular modulator of behavior as a drug target”. Trends in Pharmacological Sciences. 30 (3): 105—11. PMID 19211160. doi:10.1016/j.tips.2008.11.006. 
10. ^ Blundell J, Hoang CV, Potts B, Gold SJ, Powell CM (2008). „Motor coordination deficits in mice lacking RGS9”. Brain Research. 1190: 78—85. PMC 2241663 . PMID 18073128. doi:10.1016/j.brainres.2007.11.017. 

Literatura

• Bonaldo MF, Lennon G, Soares MB (1997). „Normalization and subtraction: two approaches to facilitate gene discovery.”. Genome Res. 6 (9): 791—806. PMID 8889548. doi:10.1101/gr.6.9.791. 
• Cowan CW; Fariss RN; Sokal I; et al. (1998). „High expression levels in cones of RGS9, the predominant GTPase accelerating protein of rods.”. Proc. Natl. Acad. Sci. U.S.A. 95 (9): 5351—6. PMC 20264 . PMID 9560279. doi:10.1073/pnas.95.9.5351. CS1 одржавање: Експлицитна употреба et al. (веза)
• Granneman JG; Zhai Y; Zhu Z; et al. (1998). „Molecular characterization of human and rat RGS 9L, a novel splice variant enriched in dopamine target regions, and chromosomal localization of the RGS 9 gene.”. Mol. Pharmacol. 54 (4): 687—94. PMID 9765512. CS1 одржавање: Експлицитна употреба et al. (веза)
• Zhang K; Howes KA; He W; et al. (2000). „Structure, alternative splicing, and expression of the human RGS9 gene.”. Gene. 240 (1): 23—34. PMID 10564809. doi:10.1016/S0378-1119(99)00393-5. CS1 одржавање: Експлицитна употреба et al. (веза)
• Yu H, Bondarenko VA, Yamazaki A (2001). „Inhibition of retinal guanylyl cyclase by the RGS9-1 N-terminus.”. Biochem. Biophys. Res. Commun. 286 (1): 12—9. PMID 11485301. doi:10.1006/bbrc.2001.5346. 
• Hu G, Wensel TG (2002). „R9AP, a membrane anchor for the photoreceptor GTPase accelerating protein, RGS9-1.”. Proc. Natl. Acad. Sci. U.S.A. 99 (15): 9755—60. PMC 125004 . PMID 12119397. doi:10.1073/pnas.152094799. 
• Strausberg RL; Feingold EA; Grouse LH; et al. (2003). „Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.”. Proc. Natl. Acad. Sci. U.S.A. 99 (26): 16899—903. PMC 139241 . PMID 12477932. doi:10.1073/pnas.242603899. CS1 одржавање: Експлицитна употреба et al. (веза)
• Martemyanov KA; Lishko PV; Calero N; et al. (2003). „The DEP domain determines subcellular targeting of the GTPase activating protein RGS9 in vivo.”. J. Neurosci. 23 (32): 10175—81. PMID 14614075. CS1 одржавање: Експлицитна употреба et al. (веза)
• Nishiguchi KM; Sandberg MA; Kooijman AC; et al. (2004). „Defects in RGS9 or its anchor protein R9AP in patients with slow photoreceptor deactivation.”. Nature. 427 (6969): 75—8. PMID 14702087. doi:10.1038/nature02170. CS1 одржавање: Експлицитна употреба et al. (веза)
• Ajit SK, Young KH (2004). „Enhancement of pheromone response by RGS9 and Gbeta5 in yeast.”. Biochem. Biophys. Res. Commun. 324 (2): 686—91. PMID 15474482. doi:10.1016/j.bbrc.2004.09.100. 
• Cheng JY; Luu CD; Yong VH; et al. (2007). „Bradyopsia in an Asian man.”. Arch. Ophthalmol. 125 (8): 1138—40. PMID 17698770. doi:10.1001/archopht.125.8.1138. CS1 одржавање: Експлицитна употреба et al. (веза)